Patients’ Health‑Related Quality of Life and Use of Medicinal Cannabis: A Cross‑Sectional Survey Study

Abstract Background: Studies on medicinal cannabis (MC) have primarily investigated effects on diseases and symptoms, while there is only sparse knowledge on patients’ health-related quality of

April 18, 2025

Patient–provider interactions about cannabis for therapeutic purposes vary as a function of provider type: A pilot study

Please use this link to access this publication. Abstract Background and Objectives Limited evidence guides the efficacy and safety of cannabis for therapeutic purposes (CTP).

December 4, 2024

Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms: Systematic review and meta-analysis

Please use this link to access this publication. Abstract Rationale Certifications for medical cannabis are generally restricted to a small number of specific medical conditions, yet patients

October 3, 2024

Patient-reported outcomes in those consuming medical cannabis: a prospective longitudinal observational study in chronic pain patients

Abstract Purpose We investigated patients with chronic pain seeking medical cannabis. We assessed their demographics, patterns of cannabis use, and the long-term effectiveness of cannabis

June 16, 2025

Patient Experience and Perspective on Medical Cannabis as an Alternative for Musculoskeletal Pain Management

Abstract Introduction: The current rate of opioid prescription is disquieting because of their high abuse potential, adverse effects, and thousands of overdose deaths. This situation

March 20, 2024

Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis

Invasion and metastasis of aggressive breast cancer cells are the final and fatal steps during cancer progression. Clinically, there are still limited therapeutic interventions for

September 19, 2019

Pathophysiological role of host microbiota in the development of obesity

Abstract Overweight and obesity increase the risk for a number of diseases, namely, cardiovascular diseases, type 2 diabetes, dyslipidemia, premature death, non-alcoholic fatty liver disease

Paternal Cannabis Exposure Prior to Mating, but Not Δ9-Tetrahydrocannabinol, Elicits Deficits in Dopaminergic Synaptic Activity in the Offspring

Abstract The legalization and increasing availability of cannabis products raises concerns about the impact on offspring of users, and little has appeared on the potential

May 20, 2024

Part 2: Drug Interactions Involving Cannabis Products in Persons Aged 18 and Over: A Summary of Published Case Reports and Analysis of the FDA Adverse Event Reporting System

ABSTRACT The increasing utilization of cannabis products combined with lack of data regarding potential cannabis–prescription drug interactions is concerning. This study aimed to review published

January 11, 2026

Part 1: Evaluation of Pediatric Cannabis–Drug Interaction Reports

ABSTRACT Data addressing safety concerns related to potential drug interactions between cannabis-derived products and pharmaceutical medications in the pediatric population are lacking. In this study,

December 13, 2025